Labiotech.eu

antibody drug conjugate adc small cancer treatment

News and Trends 14 Oct 2022

Mablink Bioscience receives €31M series A funding for ADC pipeline

French biotech company Mablink Bioscience has raised €31 million ($30.3 million) in series A funding to advance its lead candidate to the clinic and to build a pipeline of antibody drug conjugates (ADCs). The round was led by Sofinnova Partners and Mérieux Equity Partners. Existing shareholders Elaia Partners, UI-Investissement/Pertinence Invest 2 (advised by Mérieux Equity […]

October 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Oct 2022

A-Alpha Bio and Bristol Myers Squibb to collaborate on protein degradation

A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions is to collaborate with Bristol Myers Squibb to discover molecular glue targets for protein degradation. A-Alpha will identify and characterize novel pairs of E3 ubiquitin ligases and targets that Bristol Myers Squibb will utilize for potential design and development of […]

October 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

Plan launched to improve diversity of clinical trials

Help to improve the equity of clinical trials by providing site-level participant demographic data including race, sex, age and ethnicity has been revealed. Medidata, a Dassault Systèmes company, has launched the intelligent trials diversity module. The new module will help sponsors and clinical research organizations (CROs) benchmark the diversity of their trials and identify sites […]

October 13, 2022 - 3 minutesmins - By Liza Laws

News and Trends 13 Oct 2022

Agreement to take advantage of stem cells from first teeth

An agreement has been made to utilize the advantage of stem cells from human exfoliated deciduous teeth (SHED) under development by Japan-based Kidswell Bio. Kidswell is entering into the agreement with Showa Denko Materials Co., which will also enable process development as well as clinical manufacturing of cell therapy products. Under the terms of agreement, […]

October 13, 2022 - 3 minutesmins - By Liza Laws

News and Trends 13 Oct 2022

CMT Research Foundation funding boosts Samsara Therapeutics Charcot-Marie-Tooth treatment

The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease, has invested in Samsara Therapeutics Inc. Samsara Therapeutics is a biotech company focusing on discovering and developing therapeutics to restore autophagy – the process by which cells recycle damaged or dysfunctional components. Samsara is developing several novel, […]

October 13, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

Xcell Biosciences and aCGT Vector pushing ahead with cell and gene therapies

Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, and aCGT Vector, a point-of-care cell and gene therapy-as-a-service (TaaS) company, are collaborating to improve manufacturing and analytic procedures to develop personalized cell and gene therapies for cancer patients. aCGT Vector will provide its point-of-care, GMP-licensed manufacturing platform to validate Xcellbio’s […]

October 13, 2022 - 2 minutesmins - By Jim Cornall

boston bioworks precision fermentation Elena Resko

Startup Scout 13 Oct 2022

Boston Bioworks helps precision fermentation startups scale up

Precision fermentation startups have few options when looking for ways to scale up their technology. The newly launched scaling service provider Boston Bioworks aims to address this bottleneck. In the food protein industry, sustainability, climate change and animal welfare are a growing concern for many consumers, leading to soaring interest in alternative protein. This wide […]

October 13, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 13 Oct 2022

Odyssey Therapeutics raises $168M for oncology medicine portfolio

Biotech company Odyssey Therapeutics, Inc. has announced it has raised $168 million in series B financing. Odyssey Therapeutics is working on next generation precision immunomodulators and oncology medicines. The current round brings the total capital raised to $386 million. The proceeds will enable Odyssey to advance its portfolio of precision immunomodulators and oncology medicines in […]

October 13, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

Merck contributing to Jacobio Pharma colorectal cancer clinical trial

Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on a clinical study of combination therapy between Jacobio’s KRAS G12C inhibitor JAB-21822 and Merck’s epidermal growth factor receptor (EGFR) inhibitor Erbitux (cetuximab). This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated […]

October 13, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

T-cell therapy platform trial begins in adults with blood cancers

SMART102, a human T-lymphoid progenitor cell injection derived from cord blood using Smart Immune’s ProTcell platform, has entered clinical testing. The trial is being sponsored and led by Great Paris University Hospitals (AP-HP). Smart Immune SAS is a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell therapy platform to fully and rapidly re-arm the immune […]

October 13, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

Skin microbiome research could lead to new approaches for addressing organ damage after stem cell transplants

Skin microbiome research could lead to new approaches for addressing organ damage after stem cell transplants. Organ damage occurs in up to 70% of patients in the first few months following stem cell transplant. The reasons for this potentially life-threatening reaction have long been the subject of scientific research. Now, researchers led by Georg Stary […]

October 13, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

Inotrem says septic shock trial yields positive results

Clinical stage biotech company Inotrem has announced results from its phase IIb ASTONISH clinical trial in septic shock patients. The results were revealed at the International Sepsis Forum in Barcelona, Spain. Study details ASTONISH was designed to show the efficacy of nangibotide in septic shock with a precision medicine approach aiming to identify patients who […]

October 13, 2022 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Mablink Bioscience receives €31M series A funding for ADC pipeline

A-Alpha Bio and Bristol Myers Squibb to collaborate on protein degradation

Plan launched to improve diversity of clinical trials

Agreement to take advantage of stem cells from first teeth

CMT Research Foundation funding boosts Samsara Therapeutics Charcot-Marie-Tooth treatment

Xcell Biosciences and aCGT Vector pushing ahead with cell and gene therapies

Boston Bioworks helps precision fermentation startups scale up

Odyssey Therapeutics raises $168M for oncology medicine portfolio

Merck contributing to Jacobio Pharma colorectal cancer clinical trial

T-cell therapy platform trial begins in adults with blood cancers

Skin microbiome research could lead to new approaches for addressing organ damage after stem cell transplants

Inotrem says septic shock trial yields positive results

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!